Volinanserin

Volinanserin

Sedative and Hypnotic Drugs

Published in Sahab Uddin, Rashid Mamunur, Advances in Neuropharmacology, 2020

Volinanserin, eplivanserin, and pruvanserin are the new 5-HT2A serotonin receptor subtype agents. As compared with existing antidepressants with sedative action, they have least affinity for dopamine, histamine, and adrenergic receptors. These drugs have shown efficacy in maintenance of sleep and also increases in slow wave pattern of sleep. Eplivanserin was discontinued during development stages for unknown reasons. The drug development of volinanserin and pruvanserin were stopped despite having positive efficacy data of phase III clinical trial (Teegarden et al., 2008).

Emerging 5-HT receptor antagonists for the treatment of Schizophrenia

View Article

Journal Information

Published in Expert Opinion on Emerging Drugs, 2020

Mackenzie T. Jones, Martin T. Strassnig, Philip D. Harvey

Ritanserin and volinanserin were some of the first of these drugs to be evaluated for schizophrenia. Because development of the drug was aborted, we do not know if the failure of volinanserin was because it was being used to treat acute psychosis rather than a targeted treatment for negative symptoms. However, if roluperidone was to succeed, subsequent efforts could be launched. Guanfacine was a little-used anti-hypertensive agent that was redeveloped for ADHD.

Explore chapters and articles related to this topic

Sedative and Hypnotic Drugs

Emerging 5-HT receptor antagonists for the treatment of Schizophrenia